WhatsApp

A New Option for Advanced Esophageal Cancer: Tislelizumab Shows Promise

You are here >> Home > Latest Updates >Esophagus Cancer> A New Option…

Tislelizumab efficacy and safety compared to other anti-PD-1s a network meta-analysis of first-line therapi.DOI 10.3389fimmu.

Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal cancer.

When it’s advanced or has spread, surgery is no longer possible, and treatment options are limited. Now, a new immune-based therapy is showing strong results.

This study looked at three similar treatments—tislelizumab, nivolumab, and pembrolizumab—each combined with standard chemotherapy.

These medicines are called PD-1 inhibitors, and they help the immune system fight cancer.

The results showed that tislelizumab worked just as well as the other two drugs when it came to helping patients live longer.

It also helped slow down the cancer’s growth more effectively than nivolumab. All three treatments had similar safety, with no major differences in side effects.

Tislelizumab may be especially helpful for patients with high levels of a protein called PD-L1, but it also worked well across different patient groups, including people from Asia and other parts of the world.

This gives doctors another reliable option for treating advanced ESCC—and offers patients more hope with immune-based therapies that are tailored to the body’s own defenses.

Rate this post
Dr. Harsh J Shah